Drug intelligence / Profile preview

SNC-113

Development stage: Unknown
Lead developer: Simnova Biotherapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies

Overview

SNC-113 is an investigational cell therapy classified as a CAR-NK (chimeric antigen receptor natural killer) product. It is being developed by Shanghai Simnova Biotechnology for the treatment of neoplasms, specifically solid tumors. The drug is currently in the discovery phase and has not yet entered clinical trials or received regulatory approval. Its mechanism of action involves genetically engineered NK cells designed to target and destroy cancer cells expressing specific antigens associated with solid tumors[1][2].

Beyond the preview

Go deeper on SNC-113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNC-113.

Explore the full profile